Rindopepimut
Alternative Names: ALT 110; Brain cancer vaccine - Celldex Therapeutics; CDX-110; PF-04948568; PF-04948569; PF-4948568; PF-4948569; Rindo; Rintega; SPX 110Latest Information Update: 05 Nov 2023
At a glance
- Originator Duke University; Johns Hopkins University
- Developer Celldex Therapeutics Inc
- Class Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glioblastoma; Solid tumours
Most Recent Events
- 16 Oct 2017 Expanded access no longer available for rindopepimut in Glioblastoma (Recurrent, Second-line therapy or greater) (NCT03068650)
- 08 Aug 2016 Discontinued - Phase-I for Solid tumours in USA (Intradermal)
- 08 Aug 2016 Discontinued - Phase-II for Glioblastoma (Combination therapy, Second-line therapy or greater) in USA (Intradermal)